Companies whose revenues in the UK are shaped by the government’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which will end next year, faced a difficult decision last month.
UK: Will Companies Remaining In Voluntary Payment Scheme End Up With A Bigger Bill?
Uncertainty over the payments that will be due from companies to manage the branded medicines bill in 2023 and beyond has been a cause for concern for firms, which last month had to decide whether to remain in or exit the Voluntary Scheme for Branded Medicines Pricing and Access. If many companies have left, the “remainers” might end up paying more than their fair share, though the government has offered some assurance on this front.
More from United Kingdom
• By
While the pharma industry appears to be exempt from US tariffs imposed by President Trump, a member of the UK House of Lords says the details are unknown and warned that uncertainty “leads to less investment” in business as a whole.
The UK government has listened to industry concerns about high clawback rates under the voluntary scheme and will review it in June in a bid to resolve the issue and “move on to bigger and more important things,” health secretary Wes Streeting says.
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
More from Europe
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.